TGF-β1 of no avail as prognostic marker in lyme disease
Background. Within the present in vivo study using the wild type mouse strains C3H/HeN and FVB/N it was intended to (1) measure TGF-β1 expression in the course of lyme disease, (2) examine the potential correlation of TGF-β1 expression with the clinical outcome of a Borrelia infection (with a focus...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2014-05-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/398.pdf |
| _version_ | 1827605566815469568 |
|---|---|
| author | Julia Schumann |
| author_facet | Julia Schumann |
| author_sort | Julia Schumann |
| collection | DOAJ |
| description | Background. Within the present in vivo study using the wild type mouse strains C3H/HeN and FVB/N it was intended to (1) measure TGF-β1 expression in the course of lyme disease, (2) examine the potential correlation of TGF-β1 expression with the clinical outcome of a Borrelia infection (with a focus on lyme arthritis), (3) develop a diagnostic tool based on the endogenous factor TGF-β1 to predict the progressivity of lyme disease.Findings. In the course of lyme disease there was an increase in the serum content of active TGF-β1, which became significant 56 days post infection (p < 0.001). The serum concentration of total TGF-β1 in the course of infection initially decreased then rebounded and subsequently dropped again. Despite considerable individual variations in active TGF-β1 serum concentrations there were no identifiable dissimilarities in the clinical appearance of the mice. Likewise, no correlation could be seen between the serum content of active TGF-β1 and the severity of lyme arthritis of tibiotarsal joints of infected mice.Conclusions. The present study clearly shows that TGF-β1 is of no avail as prognostic marker in lyme disease. Hence, the search for an endogenous predictive factor, which can be determined in an easy and reliable manner, remains open. |
| first_indexed | 2024-03-09T06:23:32Z |
| format | Article |
| id | doaj.art-235f67c2ec1b4259953366576ef65134 |
| institution | Directory Open Access Journal |
| issn | 2167-8359 |
| language | English |
| last_indexed | 2024-03-09T06:23:32Z |
| publishDate | 2014-05-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj.art-235f67c2ec1b4259953366576ef651342023-12-03T11:30:13ZengPeerJ Inc.PeerJ2167-83592014-05-012e39810.7717/peerj.398398TGF-β1 of no avail as prognostic marker in lyme diseaseJulia Schumann0Center for Biotechnology and Biomedicine (BBZ), Faculty of Veterinary Medicine, University of Leipzig, Leipzig, GermanyBackground. Within the present in vivo study using the wild type mouse strains C3H/HeN and FVB/N it was intended to (1) measure TGF-β1 expression in the course of lyme disease, (2) examine the potential correlation of TGF-β1 expression with the clinical outcome of a Borrelia infection (with a focus on lyme arthritis), (3) develop a diagnostic tool based on the endogenous factor TGF-β1 to predict the progressivity of lyme disease.Findings. In the course of lyme disease there was an increase in the serum content of active TGF-β1, which became significant 56 days post infection (p < 0.001). The serum concentration of total TGF-β1 in the course of infection initially decreased then rebounded and subsequently dropped again. Despite considerable individual variations in active TGF-β1 serum concentrations there were no identifiable dissimilarities in the clinical appearance of the mice. Likewise, no correlation could be seen between the serum content of active TGF-β1 and the severity of lyme arthritis of tibiotarsal joints of infected mice.Conclusions. The present study clearly shows that TGF-β1 is of no avail as prognostic marker in lyme disease. Hence, the search for an endogenous predictive factor, which can be determined in an easy and reliable manner, remains open.https://peerj.com/articles/398.pdfInflammatory lessionsLyme diseaseTGF-β1Prognostic marker |
| spellingShingle | Julia Schumann TGF-β1 of no avail as prognostic marker in lyme disease PeerJ Inflammatory lessions Lyme disease TGF-β1 Prognostic marker |
| title | TGF-β1 of no avail as prognostic marker in lyme disease |
| title_full | TGF-β1 of no avail as prognostic marker in lyme disease |
| title_fullStr | TGF-β1 of no avail as prognostic marker in lyme disease |
| title_full_unstemmed | TGF-β1 of no avail as prognostic marker in lyme disease |
| title_short | TGF-β1 of no avail as prognostic marker in lyme disease |
| title_sort | tgf β1 of no avail as prognostic marker in lyme disease |
| topic | Inflammatory lessions Lyme disease TGF-β1 Prognostic marker |
| url | https://peerj.com/articles/398.pdf |
| work_keys_str_mv | AT juliaschumann tgfb1ofnoavailasprognosticmarkerinlymedisease |